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The attitude to antibacterial therapy needs to be fun-
damentally changed. After the period of indisputable 
efficient outcomes of treatment (Aminov, 2010) and 
intensive search for new substances with a wide spec-
trum activity and better pharmacological characteris-
tics, a crisis in antibiotic therapy has emerged (Davies, 
2014). This situation results from the underestimated 
plasticity of bacterial genomes and ability to accumulate 
features, which allow bacteria to endure environment 
which is hostile and rich in antibacterial substances. 
A vital example of this kind of environment is an organ-
ism of a person treated with antibiotics (Ambur et al., 
2009). Increasing frequency of multi-drug resistance 
hinders the ability to treat patients in life-threatening 
conditions. Unreasonable antibacterial therapy is sus-
pected to be the main reason of the problem. 
The most common causes of the community acqui-
red respiratory infections in children over 3 years old 
and adults are viruses (respectively up to 85% and 95%): 
respiratory syncytial virus (RSV), influenza and parain-
fluenza viruses, adenoviruses and even rhinoviruses 
(Korppi et al., 2004; Macfarlane et al., 2001). According 
to Jennings et al. (2008), bacterial pathogens isolated 
from adults were Streptococcus pneumoniae, Haemo­
philus influenzae, Mycoplasma pneumoniae, Legionella 
pneumophila and Staphylococcus aureus.
Large national, European and worldwide programs 
have been started in order to improve the situation 
(WHO, 2014a; National Institute of Allergy and Infec-
tious Diseases, 2014; National Medicines Institute, 
2014; ECDC, 2014). In the presented study the rele-
vance between the number of doses of different antibi-
otic types prescribed for patients and autumn-winter 
season with the increased number of viral infections 
was examined. 
Data on the number of systemic-use antibiotics pre-
scribed between July 2009 and June 2014 was obtained 
from a leading twenty-four-hour pharmacy located in 
the city center of Szczecin, Poland, and was grouped 
according to the drug’s active substance. Due to its 
location and local conditions, for most of the analyzed 
period, the pharmacy, aside from its regular activ-
ity, was the only one to serve patients at night and on 
public holidays. Data obtained from an internal phar-
macy system have been converted into the consumed 
DDDs (defined daily doses) according to WHO guide-
lines and ATC/DDD Index 2014 (WHO, 2014b) and 
divided according to a month of prescription. Months 
from October to March were classified as viral infec-
tions “season”, which correlates with autumn/winter 
period in the Polish climate zone. Months from April 
to September were classified as “out of season”, which 
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is characterized by a significant decrease in viral infec-
tions in Europe (Bollaerts et al., 2013). Data has also 
been divided according to antibiotic classes and drug 
form type. Afterwards, data was converted into DDDs 
per 1000 inhabitants. As a part of those calculations, 
a number of all prescriptions in the analyzed pharmacy 
was used, as well as a number of all prescriptions in 
all pharmacies in Szczecin over the respective periods 
of time. Data on prescriptions dispensed in the entire 
city has been obtained from the records of the Polish 
National Health Fund (NFZ). The population of Szcze-
cin, according to the Central Statistical Office Report 
(2013) (Central Statistical Office, 2013) was calculated 
as 408 502 people. In order to determine the age struc-
ture of patients for whom antibiotics in 2012/2013 sea-
son and 2013 out-of-season periods were prescribed, 
prescriptions were divided by patients’ age. Differences 
between numbers of DDDs consumed in season and 
out of season, noticed in the analyzed data, were statis-
tically tested using Statsoft STATISTICA 10 software. 
Statistical tests were chosen according to Statsoft guide-
lines based on Cobb (1998) publication, depending on 
results’ distribution in the analyzed groups: t-test or 
Mann-Whitney U test. 
Conducted research comprised information on pre-
scriptions for 42 997 drug packages with antibiotics for 
systemic use, which relates to 369 909 DDDs of active 
substances, dispensed in a four-year period. Averages 
of DDDs consumption per 1000 inhabitants in different 
seasons and out of season period are shown in Table I. 
The number of prescribed penicillins, cephalosporins 
and macrolides (which are the most frequently pre-
scribed antibiotic classes) in season always surpassed 
the quantity in “out of season” periods. As far as lin-
cosamides are concerned, the trend was exactly oppo-
site. For tetracyclines, quinolones, and sulphonamides 
the results are divergent in different years. As far as dif-
ferent drug forms were analyzed, the increase in season 
was noticed in both tablets and suspensions.
Overall fluctuations in the number of the prescribed 
antibiotics are shown in Fig. 1.
Fluctuations were significantly different for vari-
ous classes of antibiotics, as shown in Table I. The larg-
est differences were noticed for cephalosporins (e.g. 
60.71 DDDs/1000 inhabitants in season 2012/2013 in 
comparison to 26.96  DDDs/1000 inhabitants in out-
of-season 2012), macrolides (e.g. 79.69  DDDs/1000 
inhabitants in season 2012/2013 in comparison to 
36.27 DDDs/1000 inhabitants in out-of-season 2012), 
penicillins (e.g. 145.90 DDDs/1000 inhabitants in sea-
son 2009/2010 in comparison to 74.09 DDDs/1000 
inhabitants in out-of-season 2009), sulphonamides (e.g. 
11.17 DDDs/1000 inhabitants in season 2012/2013 in 
comparison to 5.59 DDDs/1000 inhabitants in out-of-
season 2012) and tetracyclines (e.g. 40.52 DDDs/1000 
inhabitants in season 2012/2013 in comparison to 
29.23 DDDs/1000 inhabitants in out-of-season 2012).
The scale of the observed differences depended also 
on the type of a drug form. The term “Tablets” also 
refers to capsules. The term “Suspensions” also refers 
to syrups and solid dry forms intended for dissolution 
in water and oral administration as a suspension. Tak-
ing into account pharmaceutical practice, suspensions 
are predominantly prescribed in treatment of children. 
Larger differences were observed for suspensions (e.g. 
34.74 DDDs/1000 inhabitants in season 2009/2010 in 
comparison to 11.95 DDDs/1000 inhabitants in out-
of-season 2009) than for much more often prescribed 
tablets (e.g. 384.06 DDDs/1000 inhabitants in season 
2012/2013 in comparison to 220.63 DDDs/1000 inhab-
itants in out-of-season 2012). Statistical analysis results 
are shown in Table II.
For the age groups 0–10, 21–30 and over 70 years 
old there were prescribed the highest number of anti-
TOTAL  370.08 428.24 329.82 443.72 245.30 263.40 228.54 361.69 282.62 316.67 186.46
Penicillins 164.57 189.71 147.95 197.75 110.14 117.95 98.39 173.37 131.43 145.90 74.09
Cephalosporins 48.60 59.08 39.12 60.71 26.96 30.72 23.13 35.73 26.47 28.27 12.75
Macrolides 45.97 65.00 42.55 79.69 36.27 44.25 33.62 60.90 45.15 53.07 31.15
Lincosamides 23.82 20.89 20.96 19.60 14.18 13.59 15.36 14.12 12.79 11.38 9.11
Tetracyclines 48.15 47.61 39.79 40.52 29.23 31.12 33.07 46.85 39.18 42.73 31.65
Quinolones 23.84 30.38 27.02 29.60 20.29 15.96 14.07 16.08 18.11 21.16 17.53
Sulphonamides 9.66 8.59 7.60 11.17 5.59 6.86 6.02 10.68 6.09 9.70 6.43
Suspensions 37.09 47.15 31.62 59.47 24.48 27.59 19.55 63.72 24.27 34.74 11.95
Tablets 332.46 380.85 297.97 384.06 220.63 235.64 208.61 297.57 258.05 281.56 174.04
Table I
Averages of systemic-use antibiotic consumption (DDDs per 1000 inhabitants) in viral infections seasons (Oct-Mar)






































bio tics, based on the number of prescriptions in sea-
son 2012/2013 and out of season period in 2013. The 
largest increase in the number of prescriptions in the 
abovemen tioned season in comparison with out-of-
season period was observed in age groups 41–60 and 
71 and older. 
According to the data collected by the European 
Centre for Disease Prevention and Control (ECDC, 
2013a) consumption of antibacterial agents for sys-
temic use (primary care sector, no hospital use) as well 
as antibiotic distribution systems vary significantly in 
European countries. In Scandinavian countries, e.g. in 
Sweden antibiotic consumption is at the lowest level 
in Europe (e.g. in 2012 – 14.1 DDDs per 1000 inhabit-
ants per day) (ECDC, 2013b), which can be directly 
linked with prescription-only distribution system, high 
awareness among specialists, patients and also efficient 
national efforts to reduce the problem of bacterial resist-
ance (Malmvall et al., 2007). The opposite situation is 
in France, where the consumption of antibiotics is at 
 362.75 270.29 34.21% significant 0.000066
Classification by antibiotic group
Cephalosporins 42.90 28.76 49.18% significant 0.001201
Quinolones 22.64 19.94 13.49% insignificant –
Lincosamides 15.92 15.74 1.11% insignificant –
Macrolides 60.58 39.02 55.28% significant 0.000004
Penicillins 164.94 120.16 37.27% significant 0.000239
Sulphonamides 9.40 6.62 41.93% significant 0.002510
Tetracyclines 41.77 36.00 16.03% significant 0.033546
Classification by drug form
Suspensions 46.53 24.53 89.72% significant 0.000003
Tablets 315.94 245.44 28.72% significant 0.001265
Table II
Averages of antibiotic consumption in division by antibiotic group and drug form with statistical analysis results.









Fig. 1. Overall fluctuations in the number of the prescribed antibiotics (DDD per 1000 inhabitants).
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the highest level in Europe (in 2012–29.7 DDDs per 
1000 inhabitants per day) (ECDC, 2013b), which might 
be connected with the wide availability of antibiotics 
and frequent prescribing by primary care practitioners 
(Humphreys, 2011; Grimaldi-Bensouda et al., 2014). In 
Polish healthcare system, antibiotics for systemic use 
are prescription-only drugs, nonetheless the awareness 
of the problem of unreasonable antibacterial therapy 
seems to be quite low (Panasiuk et al., 2010; Godycki-
Cwirko et al., 2014). Therefore Poland is placed in the 
middle of the ECDC list (in year 2012 –22.6 DDDs per 
1000 inhabitants per day) (ECDC, 2013b).
The connection between seasonal variability of 
outpatient antibiotic use in European countries and 
reasonable antibacterial therapy has already been 
described by Goossens et al. (2005) in Lancet. In coun-
tries where antibiotic consumption has been highest 
(with France as a leading country), fluctuations have 
been most significant. On the contrary, in countries 
with low consumption of antibiotics and restricted pol-
icy for antibiotics usage, seasonal fluctuations have been 
very low. Comparing the data from the aforementioned 
article and ECDC data, the situation in Poland over 
10  years (2002–2012) has not changed substantially. 
The seasonal variability was significant and antibio - 
tics consumption in year 2002 was estimated at around 
21.4  DDDs per 1000  inhabitants per day (ECDC, 
2013b), so at even a slightly lower level than in 2012.
According to the treatment recommendations 
presented by the National Medicines Institute (2010) 
90–95% of cases of acute pharyngitis and tonsillitis in 
adults are caused by viruses (e.g. rhinoviruses, coro-
naviruses, adenoviruses, Epstein-Barr Virus, Coxackie, 
Herpes simplex, influenza and parainfluenza viruses). 
From five to ten percent of these cases are caused by 
streptococcal infections (e.g. Streptococcus pyogenes). 
According to the abovementioned document, only 
about 0.5–2% of cases of rhinitis and sinusitis are 
caused by bacterial infections (e.g. Streptococcus pneu­
moniae, Haemophilus influenzae). The aforementioned 
bacterial infections and a small percent of viral diseases 
followed by bacterial infections can justify a slight 
increase in antibiotics consumption during season in 
all analyzed countries. Unreasonable prescribing of 
antibacterial substances for likely viral infections might 
cause a more significant increase in antibiotic intake in 
the viral infections season. 
Worldwide medical recommendations, in the USA 
as well as in Poland and other European countries 
(National Medicines Institute, 2010; L’Agence Nation-
ale de Sécurité du Médicament et des Produits de Santé, 
2003; CDC, 2014) require differentiation between viral 
and bacterial etiology. According to these recommen-
dations, it is based on medical history and analysis of 
symptoms but also on rapid infection tests like RS virus 
test (Slinger et al., 2004), influenza A/B tests (Ko et al., 
2013) and streptococcal antigen tests (Lean et al., 2014). 
Despite well-defined recommendations, this kind of 
rapid diagnostic tests is restricted in the primary care 
system in Poland. The decision on the course of treat-
ment is usually empirical and not preceded by com-
prehensive diagnostics. Because of the lack of rational 
antibiotic prescriptions in the light of microbial diag-
nostics, the most frequently used antibacterial agents 
are wide-spectrum penicillins and cephalosporins. The 
high prevalence of macrolides (especially azithromycin) 
might result from a simple dosing scheme and shortage 
of information about potential penicillin hypersensi-
tivity in patients. Particularly high fluctuations in the 
consumption of oral suspensions might indicate that 
children are the largest group of patients subjected to 
unjustified antimicrobial therapy.
Obtained results show that unreasonable antibiotic 
treatment still poses a serious problem in Szczecin 
area. Despite the introduction of the Polish National 
Antimicrobial Surveillance Program in 2004, which 
propagates rational antibacterial therapy (Hryniewicz, 
2011; Mazińska and Hryniewicz, 2010; National Medi-
cines Institute, 2014), further actions need to be taken. 
Unfortunately, in the Polish primary care system, anti-
microbial agents are still too frequently and unreason-
ably prescribed for the treatment of cold-like infections, 
especially in children (0–10  years old), young adults 
(21–30 years old) and elderly people (over 70 years old). 
Furthermore, rapid diagnostics tests are not common 
in Polish primary care system. It is essential to enhance 
the knowledge about different causes of infections and 
methods of differentiating them among physicians and 
pharmacists. 
Presented study shows that changes in attitude to 
rational antibacterial therapy proceed too slowly and 
need permanent monitoring. According to ECDC 
data, the situation in various European countries hasn’t 
changed significantly over past decade. In the era of 
globalization and common travelling of people between 
countries and continents, the problem of multi-resistant 
bacteria has become international and might be escalat-
ing in the following years.
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